A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Alpelisib (Primary) ; Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 19 Oct 2018 Status changed from active, no longer recruiting to completed.
- 17 Jul 2018 Planned End Date changed from 28 Dec 2018 to 24 Dec 2018.
- 17 Jul 2018 Planned primary completion date changed from 28 Dec 2018 to 24 Dec 2018.